Progression to type 2 diabetes among post–myocardial infarction patients with overweight or obesity: a real-world cohort study
Main finding · Progression to T2DResult — go to the resultHazard ratio 18.3 95% CI 15.2–22.1Authors' conclusion
In real-world patients with recent myocardial infarction and overweight or obesity, prediabetes was much stronger associated with progression to type 2 diabetes than previously reported in the SELECT trial. Further, we estimated that treatment with semaglutide might be able to substantially reduce progression to type 2 diabetes.
Study context
- Population
- Patients with first-time MI and body mass index (BMI) ≥ 27 kg/m² without diabetes (SELECT-eligible), Western Denmark Heart Registry
- Participants
- 1,385 / 3,751 / 3,647
- Exposure
- Prediabetes vs normoglycemia
- Prediabetes6.0-6.4%n = 1,385
- Prediabetes5.7-6.4%n = 3,751
- Normoglycemian = 3,647reference
- Outcome
- Progression to T2D
- Follow-up
- 5 years
Methodological detailsregistry-based, real-world
- Registry-based
- Real-world
Main finding
As reported in the abstract
Hazard ratio
18.3
95% CI 15.2–22.1
Prediabetes6.0-6.4%vs Normoglycemia
HR 18.3 (95% CI 15.2–22.1)
- Estimated number-needed-to-treat (NNT5) with semaglutide to prevent one case of T2D, prediabetes6.0-6.4%
- 2.7
Observational data: associations, not effects.
Further findings
- Estimated 5-year NNT with semaglutide to prevent one case of T2D (based on SELECT) · 5 years — Prediabetes6.0-6.4%
- 2.7
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Progression to type 2 diabetes among post–myocardial infarction patients with overweight or obesity: a real-world cohort study. Cardiovasc Diabetol. Published 24 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →